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and implement a Quality Improvement (QI) project
addressing the process for administration and drug moni-
toring for patients receiving these drugs by implementing
the Institute for Healthcare Improvement (IHI) model for QI.
The IHI model utilizes the Plan-Do-Study-Act process in
which a series of small tests of change are implanted to
achieve desired results. The team established the standard
nursing practice as administration of tacrolimus or cyclo-
sporine through the white lumen of the tunneled CVC and
lab draws for drug monitoring through the red lumen of the
tunneled CVC. BMT nurses were informed of the new stan-
dard practice during twice daily safety huddles. Nurses were
instructed to remember the standard as “red for blood”
meaning to draw from the red lumen. Since implantation of
this standard practice there have been zero reported line
contaminations.499
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Background: Hemorrhagic cystitis is a complication that
may arise following Stem Cell Transplantation (SCT) as
a result of bladder inﬂammation, injury, and clot formation
that may progress to renal failure. It occurs in approximately
30 percent of SCT patients as a result of the toxic effects of
antineoplastic alkalinic agents including Cyclophosphamide,
Ifosphamide, Busulfan, immunosuppressant therapy, radia-
tion therapy, graft versus host disease (GVHD), and viral,
bacterial, and fungal infections. The treatment of choice for
hemorrhagic cystitis is continuous bladder irrigation (CBI) to
instill solutions and medications directly into the bladder.
Nursing interventions during CBI require extensive knowl-
edge about the disease and multiple conditions that cause
bladder hemorrhage. Currently, there is no formal training
program about CBI for nurses on the SCT unit; nursing staff
obtain bladder irrigation information from guidelines avail-
able from the institutional intranet website and from peers.
Purpose: The purpose of this project is to prepare new
nurses in the SCT unit to provide evidence-based care for
patients experiencing CBI treatment, to educate them on the
etiology of hemorrhagic cystitis treatments used to aid in the
healing of the bladder, and to prevent or intervene when
complications arise. Recently, a need for education was
identiﬁed due to a surge of new nursing staff hired to the SCT
unit.
Intervention: The clinical educator developed an educa-
tional program consisting of four modules about managing
patients with hemorrhagic cystitis with CBI for nurses in the
SCT unit. Malcolm Knowles’ theory of andragogy was used to
guide the program as it considers needs educators must
address when teaching an adult audience.
Results/Evaluation: A post-test was administered at the end
of the CBI educational program to evaluate knowledge
improvement and program evaluation. The CBI educational
program will also be included as part of the annual SCT staff
competency and added to orientation program for the new
SCT nurse.
Discussion: Nurses in SCT units need to be vigilant for
complications such as hemorrhagic cystitis. Development ofsuch educational programs improves nursing knowledge and
strengthens clinical practice in an area that requires expert
nursing care to support positive patient outcomes.500
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The 2006 Census estimates that the total Aboriginal
Australian population is 458,520 which is 2.4% of Australia's
population. As with other indigenous peoples worldwide
this population has been shown to have unique and signiﬁ-
cant health requirements. These necessitate cohesive part-
nerships between the health care teams and the Aboriginal
people to further improve health outcomes. Much of the
literature about health needs of Aboriginal Australians is
concerning primary health care. There is a paucity of
evidence surrounding the management of Aboriginal people
undergoing a Hematopoietic Progenitor Cell (HPC) trans-
plant, including identiﬁcation of suitable donors and
appropriate therapeutic medical management.
Currently there are few donors who identify themselves
as of Aboriginal descent. The powerful ethnic bias in the
European, North American and Australian bone marrow
registries towards northern Caucasian descent hinders the
identiﬁcation of suitably matched donors. In an attempt to
address the deﬁciency of suitable donors for the Aboriginal
person, the Sydney Cord blood bank developed an initiative
to collect cord blood units in regional and rural areas to
increase the cord blood units collectedwith the unique tissue
typing found in Aboriginal people.
The difﬁculties in donor identiﬁcation and increased
transplant complications were evident when a 17 year old
Aboriginal man presented with secondary acute myeloid
leukaemia requiring HPC transplant. The search process will
be discussed, speciﬁcally addressing the complexities in
identifying a suitable donor and the unique pharmacoki-
netics in Aboriginal people which may change the efﬁcacy
and toxicity proﬁle of commonly prescribed medications.
Throughout the transplant timeline the HPC team inte-
grated the principals of cultural safety when managing this
young Aboriginal man and his family. This was achieved by
recognising the principles of awareness, safety and security
unique to Aboriginal Australians.501
Implementation of Fact Guidelines Improves Donor
Screening
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An allogeneic bone marrow transplant offers potentially
curative therapy to patients with leukemia, lymphoma,
multiple myeloma, and myelodyspastic syndrome. Identiﬁ-
cation of a human leukocyte antigenmatched donor, through
a standardized screening process, is an essential component
of the allogeneic transplant. At this transplant center, nurse
Table
Pediatric HSCT Blood Pressure Data (Day +0 to Day +5)
Number of pediatric HSCT patients 6
Patients age 6 month-14 years
Type of HSCT allogeneic matched
unrelated donor
Number of myeloablative HSCT 2 of 6
Number of reduced intensity HSCT 4 of 6
Number of patients with initial BP
parameters ordered that were above
>95% for age and height or above
age speciﬁc percentiles for birth to
12 months of age
3/6
Total number of blood pressure (BP) data
points (Day +0 to Day +5)
458
Median number of elevated systolic BPs
documented before a BP medication
was ﬁrst ordered
30
Median number of diastolic BPs
documented before a BP medication
as ﬁrst ordered
16
Median Time in hours to Initial
antihypertensive medication delivery
after elevated BPs were documented
64.5
Most frequently used antihypertensive
medications
Hydralazine (as needed)
Nicardipine (as needed)
Amlodipine
(1-2 times daily)
Enalaprilat (every
8 hours)
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based on a history and physical, review of a Health History
Questionnaire (HHQ), and various diagnostic tests. The
Foundation for the Accreditation of Cellular Therapy (FACT),
set standards of operation to promote quality medical and
laboratory practice in hematopoietic transplantation and
other cellular therapy products. Adherence to the FACT
standards helps to ensure donor eligibility thereby reducing
the risks of transmissible diseases. The HHQ guides the NP in
determining donor eligibility. A retrospective chart review of
46 medical records from January 2011 through December
2011 revealed the rate of accuracy of 60% in determining
donor eligibility based upon FACT criteria. All donors (46)
were deemed as eligible; however, only 28 met FACT criteria
for eligibility. Eighteen patients were ineligible; yet they
were medically acceptable to donate. Reasons for ineligibility
included: a missing or incomplete HHQ, a tattoo within
a year, donor lived in Europe. NPs were re-educated
regarding FACT criteria and how to use the HHQ when
determining eligibility. A tool provided a guideline for the
NPs highlighting special considerations for donors that
would make them potentially ineligible. Following these
interventions, the rate of accuracy improved to 84%. From
June 2012 to September 2012, 19 medical records were
reviewed 16 met FACT criteria for eligibility. By re-educating
NPs about FACT guidelines, NPs were able to utilize the HHQ
as a crucial step in their assessment process and improve the
rate of accuracy in determining donor eligibility thus
improving donor screening.502
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Hypertension (HTN) is a known complication of pediatric
hematopoietic stem cell transplant (HSCT). Historically, the
risks for developing HTN depend on a variety of factors which
may includeuseof calcineurin inhibitors, thepresenceof graft
versus host disease requiring steroid therapy, total body
irradiation, and standardized chemotherapy delivered during
HSCT. Uncontrolled HTN in pediatric HSCT patients may lead
to signiﬁcant life threatening complications that often affect
long term cardiac and renal outcomes. Managing pediatric
HSCT associated HTN is often a challenge due to the range of
patients ages, heights and weights which determine normal
and target blood pressure. Using a multidisciplinary
approach, we collected pilot data from 6 pediatric patients
whohad received allogeneicHSCTs fromday +0 to day +5. The
focus was to look at their hypertension management within
the ﬁrst days following their stem cell infusions. The data
consisted of blood pressure parameters ordered, documented
blood pressures, the response time for reporting HTN and the
antihypertensive medications given to patients during that
period. The table below lists the data obtained. We found 3
areas to focus improvements on. One was to educate staff on
the use of the individualized blood pressure parameters(<95% for age and height, Pediatrics 2004; 114; 555-576,
infants birth -12 months parameters, Pediatric Nephrology
(2012) 27:17-32) in the initial order set. A second area was to
educate staff on the process of taking blood pressures
according to the published guidelines followed by our
nephrology and HTN clinics. A third improvement opportu-
nitywas to decrease the time to initiation of antihypertensive
therapy. Overall the goal is to protect the pediatric patients
throughout HSCT. This is a process that the multidisciplinary
HSCT team continues to focus and improve upon, thus
impacting the outcomes for our pediatric BMT population.
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Background: At an NCI-designated Cancer Institution with
76 inpatient stem cell transplant (SCT) patients and a bur-
geoning staff, addressing continuity of care and patient
satisfaction is an on-going opportunity for growth and
innovation. Press-Ganey patient satisfaction data revealed
that patients wanted more consistency in care, improved
communication, and increased involvement in their treat-
ment plan. In response, a nurse-driven, patient-centered
initiative examined the efﬁcacy of creating individualized
care plans, customized to each patient's unique needs, in
collaboration with the patient and caregivers.
Purpose: To increase consistency of care, improve commu-
nication among nurses and patients, and raise patient satis-
faction, a nurse-developed and driven Individualized Care
Planning Process (ICPP) was developed.
Intervention: The ICPP engages nurse volunteers to be
responsible for thedevelopmentand trackingof individualized
